The use of carbon-fiber-reinforced polymers (CFRPs) for the repair and rehabilitation of reinforced concrete (RC) structures has been receiving a lot of attention. Specifically, the shear strengthening of RC members based on CFRP materials has been treated as an effective and efficient strengthening method. Previous research projects focused on the shear strengthening of RC members with unidirectional CFRP strips. Although the effectiveness of a bidirectional CFRP layout compared to a unidirectional CFRP layout was discussed in several studies, these studies only investigated the issue based on experiments. Morever, the parameters of the bidirectional CFRP layout were not clearly defined. This study investigates the performance of RC beams strengthened by bidirectional CFRP based on numerical models. A numerical model based on finite element analysis is designed. Using the numerical model, the parameters of the horizontal CFRP strips, such as the layouts of horizontal CFRP strips and the number of horizontal CFRP strips, are studied. The results show that the effect of horizontal CFRP strips is maximized if the strips are distributed along the depth. In contrast, the number of horizontal CFRP strips does not significantly affect the shear strength of RC members.

The anticancer effect of a new pyrazole derivative, KI-10F (2-(4-(2-(4-(dimethylamino) phenyl)pyridin-4-yl)-5-(3-methoxy-5-methylphenyl)-1H-pyrazol‑1-yl) acetonitrile)•3.5HCl) was evaluated in human colon cancer cells. KI-10F strongly suppressed the growth of human colon cancer cells and induced apoptosis by increasing the proportion of sub-G1 presenting apoptotic cells as well as causing cell cycle arrest at the G2/M phase. Apoptosis by KI-10F was confirmed by observation of an increase in the expression of cleaved caspase-3, caspase-8, caspase-9 and Bax, and the decrease of Bcl-2. Decreased expression of HIF-1α and VEGF, and the inhibition of HUVEC tube formation and migration showed that KI-10F effectively inhibited the angiogenesis process. Furthermore, in vivo study in a mouse xenograft model showed that KI-10F produced a stronger antitumor activity than 5-FU, a conventional anticancer drug prescribed for the treatment of colon cancer. The effects of KI-10F on tumor proliferation (PCNA), angiogenesis (CD34) and apoptosis (cleaved caspase-3) were evaluated by immunohistochemistry using isolated tumor tissue samples. Taken together, our results demonstrated that KI-10F induces apoptosis and inhibits cell growth and angiogenesis both in vitro and in vivo. We suggest that KI-10F is an effective chemotherapeutic candidate for use against colon cancer.